PRISM BioLab was founded in 2006 by a group of scientists dedicated to creating new drugs based on their technology of peptide mimetic small molecules.  More than ten years of research and development has resulted in the clinical pipelines and numerous discoveries of potential seed compounds.

Through its PepMetics™ Platform, PRISM has established a proven technology which has already generated successful compounds for what were previously thought to be “undruggable targets”.

Mission

PRISM BioLab is committed to maximizing the potential of its PepMetics Technology, transforming the “undruggable” to “druggable” with the aim of finding cures for the incurable.